Fosun Pharma to Invest RMB 414 Million in Series B Financing and Equity Transfer of Xingyao Kunze, a Liver Disease Innovative Drug Company

Source: Cailian Press

【Fosun Pharmaceutical：Plans to Invest RMB 414 Million in Series B Financing and Equity Transfer of Innovative Liver Disease Drug Company Hepa Thera】 Cailian Press, May 26 – Fosun Pharmaceutical (600196.SH) announced that its controlled subsidiary, Fosun Pharmaceutical Industry, plans to invest a total of RMB 414 million to participate in the Series B financing of Hepa Thera and acquire a portion of the equity held by its associated funds, the Suzhou Fund and the Tianjin Fund. Specifically, RMB 218 million will be used to subscribe to RMB 2.9368 million in newly increased registered capital of Hepa Thera, and RMB 197 million will be used to acquire a combined RMB 3.0865 million in existing registered capital held by the Suzhou Fund and the Tianjin Fund. Upon completion of the transaction, Fosun Pharmaceutical Industry will hold a 20.87% equity stake in Hepa Thera. The target company is primarily engaged in the research and development of innovative drugs for liver diseases. This investment constitutes a related-party transaction and aims to enrich the company’s pipeline portfolio in the field of liver disease treatment.